ALKERMES reported $497.74M in Current Liabilities for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Liabilities Change
Acadia Pharmaceuticals ACAD:US USD 125.63M 9.06M
Acorda Therapeutics ACOR:US USD 37.95M 4.07M
Amgen AMGN:US USD 15.69B 1.36B
Biogen BIIB:US USD 3.27B 653.6M
Biomarin Pharmaceutical BMRN:US USD 588.88M 67.86M
Bluebird Bio BLUE:US USD 126.73M 22.13M
Coherus Biosciences CHRS:US USD 138.69M 32.62M
Gilead Sciences GILD:US USD 11.24B 814M
Heron Therapeutics HRTX:US USD 93.88M 15.62M
Horizon Pharma HZNP:US USD 949.14M 88.52M
Intra Cellular Therapies ITCI:US USD 83.24M 5.83M
JAZZ PHA JAZZ:US USD 933.19M 120.24M
Marinus Pharmaceuticals MRNS:US USD 25.02M 3.97M
Minerva Neurosciences NERV:US USD 1.38M 819K
Nektar Therapeutics NKTR:US USD 68.2M 15.78M
Neurocrine Biosciences NBIX:US USD 537.7M 52.6M
Otsuka Holdings 4578:JP JPY 539.19B 4.81B
Regeneron Pharmaceuticals REGN:US USD 3.85B 969.9M
Revance Therapeutics RVNC:US USD 75.68M 950K
Teva Pharmaceutical Industries TEVA:US USD 11.47B 65M
Vertex Pharmaceuticals VRTX:US USD 2.43B 178.7M